Skip to search formSkip to main contentSkip to account menu

clazakizumab

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Antibodies, Monoclonal, Humanized

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Efficacy of new treatments for dactylitis of psoriatic arthritis: update of literature review
Dactylitis is a frequent disabling feature of psoriatic arthritis (PsA). Therapeutic strategy on dactylitis is not really… 
Review
2018
Review
2018
AB0937 Efficacy of new treatments on dactylitis of psoriatic arthritis: update of systematic literature review
Background Dactylitis is a frequent disabling feature of psoriatic arthritis (PsA). Therapeutic strategy on dactylitis is not… 
2014
2014
SAT0244 A Phase Iib Study of the Efficacy and Safety of Subcutaneous Clazakizumab (ANTI-IL-6 Monoclonal Antibody) with or without Methotrexate in Adults with Moderate-To-Severe Active Rheumatoid…
Background Clazakizumab (CLZ) is a humanized anti-interleukin-6 (IL-6) monoclonal antibody that potently neutralizes IL-6… 
2014
2014
Clazakizumab Shows Benefits in PsA
(ACR2014) Direct interleukin 6 blocker controls arthritis, enthesitis, and dactylitis in psoriatic arthritis. 
2014
2014
AB0423 Impact of Anti-IL-6 Monoclonal Antibody, Clazakizumab, on Patient-Reported Outcomes in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate in A Phase Iib Study
Background Clazakizumab (CLZ) is a potent, neutralizing anti-interleukin-6 (IL-6) monoclonal antibody currently in development… 
2014
2014
SAT0210 X-Ray and MRI Results from A Phase Iib Study of Subcutaneous Anti-Interleukin-6 Monoclonal Antibody Clazakizumab with or without MTX in Adults with Moderate-To-Severe Active RA and Inadequate…
Background Clazakizumab (CLZ) is a potent, neutralizing anti-interleukin (IL)-6 monoclonal antibody that is being studied in RA… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)